Cole-Parmer, a portfolio company of private equity firm GTCR, has acquired ZeptoMetrix Corp. ZeptoMetrix is a life sciences developer and manufacturer of quality control standards and verification panels used in molecular diagnostic testing for infectious diseases. The acquisition represents CP’s second acquisition in the past year, and 12th since 2014.
“The addition of ZeptoMetrix to our global commercial infrastructure enhances our shared ability to continue to support our customers in mission critical applications within the life sciences,” states Jon Salkin, president of Cole-Parmer.
ZeptoMetrix’s products, including its patented NATtrol family of products, are used by clinical testing labs to verify that molecular diagnostic instruments are performing and accurately detecting the presence of specific genetic material within a patient sample. The ZeptoMetrix product portfolio is focused on infectious disease, including women’s health, hospital acquired infections and Covid-19.